Skip to main navigation Skip to search Skip to main content

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

  • Tina J. Hieken
  • , David Zahrieh
  • , Thomas J. Flotte
  • , Roxana S. Dronca
  • , Evidio Domingo-Musibay
  • , Garth D. Nelson
  • , Carrie A. Strand
  • , Lisa A. Kottschade
  • , Heather N. Montane
  • , Mara A. Piltin
  • , Ruqin Chen
  • , Robert R. McWilliams
  • , James W. Jakub
  • , Samir S. Khariwala
  • , Arkadiusz Z. Dudek
  • , Jeffrey E. Johnson
  • , Svetomir N. Markovic
  • , Anastasios Dimou
  • , Kendall K. Tasche
  • , Matthew S. Block

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma'. Together they form a unique fingerprint.
Sort by

Keyphrases

Immunology and Microbiology